Clinical Trial Update: Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the bioavailability of Lozanoc 65 mg itraconazole capsules for prophylaxis in neutropenia patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• Lozanoc

Snippet

Sponsor: Mayne Pharma International Pty Ltd | Conditions: Neutropenia | Phase 2 | Status: COMPLETED